Amyotrophic lateral sclerosis: moving towards a new classification system

The Lancet Neurology

Volumn 15, Issue 11, 2016, Pages 1182-1194

  Al Chalabi, Ammar ^a   Hardiman, Orla ^b   Kiernan, Matthew C ^c,d   Chiò, Adriano ^e   Rix Brooks, Benjamin ^f,g   van den Berg, Leonard H ^h  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b TRINITY COLLEGE DUBLIN   (Ireland)

^c UNIVERSITY OF SYDNEY   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

^e UNIVERSITY OF TURIN   (Italy)

^f CAROLINAS MEDICAL CENTER   (United States)

^g UNIVERSITY OF NORTH CAROLINA AT CHARLOTTE   (United States)

^h UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; RILUZOLE;

AMYOTROPHIC LATERAL SCLEROSIS; ASSESSMENT OF HUMANS; BULBAR PARALYSIS; CLINICAL PRACTICE; CLINICAL RESEARCH; COGNITION; DIAGNOSTIC TEST; DISEASE CLASSIFICATION; EL ESCORIAL CRITERIA; FAMILY HISTORY; FRONTOTEMPORAL DEMENTIA; GENETIC ANALYSIS; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; INTERNATIONAL CLASSIFICATION OF DISEASES; LABORATORY TEST; MEDICAL INFORMATION; MOTOR DYSFUNCTION; MOTOR NEURON DISEASE; NEUROIMAGING; NEUROLOGIC DISEASE; NEUROLOGIST; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; PATHOPHYSIOLOGY; PATIENT CODING; PHENOTYPE; PRIORITY JOURNAL; REVIEW; CLASSIFICATION;

AMYOTROPHIC LATERAL SCLEROSIS; HUMANS;

EID: 84990942570     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(16)30199-5     Document Type: Review

References (125)

1. 1 Office of Communications and Public Liaison. NINDS. Amyotrophic Lateral Sclerosis (ALS) Fact Sheet. 14 March 2016. http://www.ninds.nih.gov/disorders/amyotrophiclateralsclerosis/detail_ALS.htm (accessed July 28, 2016).
2. 2 Rutter-Locher, Z, Turner, MR, Leigh, PN, Al-Chalabi, A, Analysis of terms used for the diagnosis and classification of amyotrophic lateral sclerosis and motor neuron disease. Amyotroph Lateral Scler Frontotemporal Degener, 2016, 1–5.
3. 3 Aran, F, Recherches sur une maladie non encore décrite du système musculaire (atrophie musculaire progressive). Arch Gén Méd 24 (1850), 172–214.
4. 4 Cruveilhier, J, La paralysie musculaire, progressive, atrophique. Bull Acad Méd 18 (1853), 546–583.
5. 5 Brain, W, Amyotrophic lateral sclerosis, 1933, Oxford University Press, Oxford.
6. 6 Brain, W, Motor neurone disease, 1962, Oxford University Press, Oxford.
7. 7 Mackay, RP, Course and prognosis in amyotrophic lateral sclerosis. Arch Neurol 8 (1963), 17–27.
8. 8 Hu, MT, Ellis, CM, Al-Chalabi, A, Leigh, PN, Shaw, CE, Flail arm syndrome: a distinctive variant of amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 65 (1998), 950–951.
9. 9 Shoesmith, CL, Findlater, K, Rowe, A, Strong, MJ, Prognosis of amyotrophic lateral sclerosis with respiratory onset. J Neurol Neurosurg Psychiatry 78 (2007), 629–631.
10. 10 Wijesekera, LC, Mathers, S, Talman, P, et al. Natural history and clinical features of the flail arm and flail leg ALS variants. Neurology 72 (2009), 1087–1094.
11. 11 Sabatelli, M, Madia, F, Conte, A, et al. Natural history of young-adult amyotrophic lateral sclerosis. Neurology 71 (2008), 876–881.
12. 12 Turner, MR, Hardiman, O, Benatar, M, et al. Controversies and priorities in amyotrophic lateral sclerosis. Lancet Neurol 12 (2013), 310–322.
13. 13 Al-Chalabi, A, Jones, A, Troakes, C, King, A, Al-Sarraj, S, van den Berg, LH, The genetics and neuropathology of amyotrophic lateral sclerosis. Acta Neuropathol 124 (2012), 339–352.
14. 14 Brooks, BR, El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial “Clinical limits of amyotrophic lateral sclerosis” workshop contributors. J Neurol Sci 124:suppl (1994), 96–107.
15. 15 Brooks, BR, Miller, RG, Swash, M, Munsat, TL, the World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 1 (2000), 293–299.
16. 16 de Carvalho, M, Dengler, R, Eisen, A, et al. Electrodiagnostic criteria for diagnosis of ALS. Clin Neurophysiol 119 (2008), 497–503.
17. 17 Carvalho, MD, Swash, M, Awaji diagnostic algorithm increases sensitivity of El Escorial criteria for ALS diagnosis. Amyotroph Lateral Scler 10 (2009), 53–57.
18. 18 Aggarwal, S, Cudkowicz, M, ALS drug development: reflections from the past and a way forward. Neurotherapeutics 5 (2008), 516–527.
19. 19 Chiò, A, ISIS Survey: an international study on the diagnostic process and its implications in amyotrophic lateral sclerosis. J Neurol 246:suppl 3 (1999), III1–III5.
20. 20 Turner, MR, Kiernan, MC, Leigh, PN, Talbot, K, Biomarkers in amyotrophic lateral sclerosis. Lancet Neurol 8 (2009), 94–109.
21. 21 Boekestein, WA, Kleine, BU, Hageman, G, Schelhaas, HJ, Zwarts, MJ, Sensitivity and specificity of the ‘Awaji’ electrodiagnostic criteria for amyotrophic lateral sclerosis: retrospective comparison of the Awaji and revised El Escorial criteria for ALS. Amyotroph Lateral Scler 11 (2010), 497–501.
22. 22 Chen, A, Weimer, L, Brannagan, T 3rd, et al. Experience with the Awaji Island modifications to the ALS diagnostic criteria. Muscle Nerve 42 (2010), 831–832.
23. 23 Costa, J, Swash, M, de Carvalho, M, Awaji criteria for the diagnosis of amyotrophic lateral sclerosis: a systematic review. Arch Neurol 69 (2012), 1410–1416.
24. 24 Douglass, CP, Kandler, RH, Shaw, PJ, McDermott, CJ, An evaluation of neurophysiological criteria used in the diagnosis of motor neuron disease. J Neurol Neurosurg Psychiatry 81 (2010), 646–649.
25. 25 Gawel, M, Kuzma-Kozakiewicz, M, Szmidt-Salkowska, E, Kamińska, A, Are we really closer to improving the diagnostic sensitivity in ALS patients with Awaji criteria?. Amyotroph Lateral Scler Frontotemporal Degener 15 (2014), 257–261.
26. 26 Krarup, C, Lower motor neuron involvement examined by quantitative electromyography in amyotrophic lateral sclerosis. Clin Neurophysiol 122 (2011), 414–422.
27. 27 Okita, T, Nodera, H, Shibuta, Y, et al. Can Awaji ALS criteria provide earlier diagnosis than the revised El Escorial criteria?. J Neurol Sci 302 (2011), 29–32.
28. 28 Schrooten, M, Smetcoren, C, Robberecht, W, Van Damme, P, Benefit of the Awaji diagnostic algorithm for amyotrophic lateral sclerosis: a prospective study. Ann Neurol 70 (2011), 79–83.
29. 29 Jang, J-S, Bae, JS, AWAJI criteria are not always superior to the previous criteria: a meta-analysis. Muscle Nerve 51 (2015), 822–829.
30. 30 Rodrigues, JM, Schulz, S, Rector, A, et al. Sharing ontology between ICD 11 and SNOMED CT will enable seamless re-use and semantic interoperability. Stud Health Technol Inform 192 (2013), 343–346.
31. 31 Rodrigues, JM, Robinson, D, Della Mea, V, et al. Semantic alignment between ICD-11 and SNOMED CT. Stud Health Technol Inform 216 (2015), 790–794.
32. 32 Kingdon, D, Afghan, S, Arnold, R, et al. A diagnostic system using broad categories with clinically relevant specifiers: lessons for ICD-11. Int J Soc Psychiatry 56 (2010), 326–335.
33. 33 Kaji, R, Kuzuhara, S, Iwasaki, Y, et al. Ultra-high dose methylcobalamin (E0302) prolongs survival of ALS: report of 7 years' randomised double-blind, phase 3 clinical trial. Neurology, 84, 2015 P7.060.
34. 34 Neuwirth, C, Burkhardt, C, Alix, J, et al. Quality control of Motor Unit Number Index (MUNIX) measurements in 6 muscles in a single-subject “round-robin” setup. PLoS ONE, 11, 2016, e0153948.
35. 35 Tartaglia, MC, Rowe, A, Findlater, K, Orange, JB, Grace, G, Strong, MJ, Differentiation between primary lateral sclerosis and amyotrophic lateral sclerosis: examination of symptoms and signs at disease onset and during follow-up. Arch Neurol 64 (2007), 232–236.
36. 36 Turner, MR, Scaber, J, Goodfellow, JA, Lord, ME, Marsden, R, Talbot, K, The diagnostic pathway and prognosis in bulbar-onset amyotrophic lateral sclerosis. J Neurol Sci 294 (2010), 81–85.
37. 37 Visser, J, van den Berg-Vos, RM, Franssen, H, et al. Disease course and prognostic factors of progressive muscular atrophy. Arch Neurol 64 (2007), 522–528.
38. 38 van den Berg-Vos, RM, Visser, J, Franssen, H, et al. Sporadic lower motor neuron disease with adult onset: classification of subtypes. Brain 126 (2003), 1036–1047.
39. 39 Ludolph, A, Drory, V, Hardiman, O, et al. A revision of the El Escorial criteria - 2015. Amyotroph Lateral Scler Frontotemporal Degener 16 (2015), 291–292.
40. 40 Gordon, PH, Cheng, B, Katz, IB, et al. The natural history of primary lateral sclerosis. Neurology 66 (2006), 647–653.
41. 41 Short, CL, Scott, G, Blumbergs, PC, Koblar, SA, A case of presumptive primary lateral sclerosis with upper and lower motor neurone pathology. J Clin Neurosci 12 (2005), 706–709.
42. 42 Le Forestier, N, Maisonobe, T, Piquard, A, et al. Does primary lateral sclerosis exist? A study of 20 patients and a review of the literature. Brain 124 (2001), 1989–1999.
43. 43 Brugman, F, Veldink, JH, Franssen, H, et al. Differentiation of hereditary spastic paraparesis from primary lateral sclerosis in sporadic adult-onset upper motor neuron syndromes. Arch Neurol 66 (2009), 509–514.
44. 44 Van den Berg-Vos, RM, Visser, J, Kalmijn, S, et al. A long-term prospective study of the natural course of sporadic adult-onset lower motor neuron syndromes. Arch Neurol 66 (2009), 751–757.
45. 45 Vucic, S, Kiernan, MC, Abnormalities in cortical and peripheral excitability in flail arm variant amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 78 (2007), 849–852.
46. 46 Swash, M, Why are upper motor neuron signs difficult to elicit in amyotrophic lateral sclerosis?. J Neurol Neurosurg Psychiatry 83 (2012), 659–662.
47. 47 Menon, P, Geevasinga, N, Yiannikas, C, Howells, J, Kiernan, MC, Vucic, S, Sensitivity and specificity of threshold tracking transcranial magnetic stimulation for diagnosis of amyotrophic lateral sclerosis: a prospective study. Lancet Neurol 14 (2015), 478–484.
48. 48 Vucic, S, Cheah, BC, Yiannikas, C, Kiernan, MC, Cortical excitability distinguishes ALS from mimic disorders. Clin Neurophysiol 122 (2011), 1860–1866.
49. 49 Chiò, A, Calvo, A, Moglia, C, Mazzini, L, Mora, G, the PARALS study group. Phenotypic heterogeneity of amyotrophic lateral sclerosis: a population based study. J Neurol Neurosurg Psychiatry 82 (2011), 740–746.
50. 50 Burrell, JR, Vucic, S, Kiernan, MC, Isolated bulbar phenotype of amyotrophic lateral sclerosis. Amyotroph Lateral Scler 12 (2011), 283–289.
51. 51 Hu, WT, Seelaar, H, Josephs, KA, et al. Survival profiles of patients with frontotemporal dementia and motor neuron disease. Arch Neurol 66 (2009), 1359–1364.
52. 52 Lomen-Hoerth, C, Murphy, J, Langmore, S, Kramer, JH, Olney, RK, Miller, B, Are amyotrophic lateral sclerosis patients cognitively normal?. Neurology 60 (2003), 1094–1097.
53. 53 Phukan, J, Elamin, M, Bede, P, et al. The syndrome of cognitive impairment in amyotrophic lateral sclerosis: a population-based study. J Neurol Neurosurg Psychiatry 83 (2012), 102–108.
54. 54 Montuschi, A, Iazzolino, B, Calvo, A, et al. Cognitive correlates in amyotrophic lateral sclerosis: a population-based study in Italy. J Neurol Neurosurg Psychiatry 86 (2015), 168–173.
55. 55 Bensimon, G, Lacomblez, L, Meininger, V, the ALS/Riluzole Study Group. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 330 (1994), 585–591.
56. 56 Johnston, CA, Stanton, BR, Turner, MR, et al. Amyotrophic lateral sclerosis in an urban setting: a population based study of inner city London. J Neurol 253 (2006), 1642–1643.
57. 57 Harold, D, Abraham, R, Hollingworth, P, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet 41 (2009), 1088–1093.
58. 58 Turner, MR, Barnwell, J, Al-Chalabi, A, Eisen, A, Young-onset amyotrophic lateral sclerosis: historical and other observations. Brain 135 (2012), 2883–2891.
59. 59 Proudfoot, M, Jones, A, Talbot, K, Al-Chalabi, A, Turner, MR, The ALSFRS as an outcome measure in therapeutic trials and its relationship to symptom onset. Amyotroph Lateral Scler Frontotemporal Degener 17 (2016), 414–425.
60. 60 Knibb, JA, Keren, N, Kulka, A, et al. A clinical tool for predicting survival in ALS. J Neurol Neurosurg Psychiatry, 2016, 10.1136/jnnp-2015-312908 published online July 26.
61. 61 Gordon, PH, Cheng, B, Salachas, F, et al. Progression in ALS is not linear but is curvilinear. J Neurol 257 (2010), 1713–1717.
62. 62 Rooney, J, Heverin, M, Vajda, A, et al. An exploratory spatial analysis of ALS incidence in Ireland over 17·5 years (1995–July 2013). PLoS ONE, 9, 2014, e96556.
63. 63 Ravits, JM, La Spada, AR, ALS motor phenotype heterogeneity, focality, and spread: deconstructing motor neuron degeneration. Neurology 73 (2009), 805–811.
64. 64 Brettschneider, J, Del Tredici, K, Irwin, DJ, et al. Sequential distribution of pTDP-43 pathology in behavioral variant frontotemporal dementia (bvFTD). Acta Neuropathol 127 (2014), 423–439.
65. 65 Schmidt, R, de Reus, MA, Scholtens, LH, van den Berg, LH, van den Heuvel, MP, Simulating disease propagation across white matter connectome reveals anatomical substrate for neuropathology staging in amyotrophic lateral sclerosis. Neuroimage 124 (2016), 762–769.
66. 66 Elamin, M, Bede, P, Montuschi, A, Pender, N, Chio, A, Hardiman, O, Predicting prognosis in amyotrophic lateral sclerosis: a simple algorithm. J Neurol 262 (2015), 1447–1454.
67. 67 Byrne, S, Walsh, C, Lynch, C, et al. Rate of familial amyotrophic lateral sclerosis: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry 82 (2011), 623–627.
68. 68 Ganesalingam, J, Stahl, D, Wijesekera, L, et al. Latent cluster analysis of ALS phenotypes identifies prognostically differing groups. PLoS ONE, 4, 2009, e7107.
69. 69 McCluskey, L, Vandriel, S, Elman, L, et al. ALS-Plus syndrome: non-pyramidal features in a large ALS cohort. J Neurol Sci 345 (2014), 118–124.
70. 70 Brooks, BR, ALS-Plus – where does it begin, where does it end?. J Neurol Sci 345 (2014), 1–2.
71. 71 Brettschneider, J, Libon, DJ, Toledo, JB, et al. Microglial activation and TDP-43 pathology correlate with executive dysfunction in amyotrophic lateral sclerosis. Acta Neuropathol 123 (2012), 395–407.
72. 72 Cardenas-Blanco, A, Machts, J, Acosta-Cabronero, J, et al. Central white matter degeneration in bulbar- and limb-onset amyotrophic lateral sclerosis. J Neurol 261 (2014), 1961–1967.
73. 73 Cistaro, A, Valentini, MC, Chiò, A, et al. Brain hypermetabolism in amyotrophic lateral sclerosis: a FDG PET study in ALS of spinal and bulbar onset. Eur J Nucl Med Mol Imaging 39 (2012), 251–259.
74. 74 Prell, T, Peschel, T, Hartung, V, et al. Diffusion tensor imaging patterns differ in bulbar and limb onset amyotrophic lateral sclerosis. Clin Neurol Neurosurg 115 (2013), 1281–1287.
75. 75 Canosa, A, Pagani, M, Cistaro, A, et al. 18F-FDG-PET correlates of cognitive impairment in ALS. Neurology 86 (2016), 44–49.
76. 76 Byrne, S, Elamin, M, Bede, P, Hardiman, O, Absence of consensus in diagnostic criteria for familial neurodegenerative diseases. J Neurol Neurosurg Psychiatry 83 (2012), 365–367.
77. 77 Byrne, S, Bede, P, Elamin, M, et al. Proposed criteria for familial amyotrophic lateral sclerosis. Amyotroph Lateral Scler 12 (2011), 157–159.
78. 78 Byrne, S, Heverin, M, Elamin, M, et al. Aggregation of neurologic and neuropsychiatric disease in amyotrophic lateral sclerosis kindreds: a population-based case-control cohort study of familial and sporadic amyotrophic lateral sclerosis. Ann Neurol 74 (2013), 699–708.
79. 79 Al-Chalabi, A, Lewis, CM, Modelling the effects of penetrance and family size on rates of sporadic and familial disease. Hum Hered 71 (2011), 281–288.
80. 80 Al-Chalabi, A, Fang, F, Hanby, MF, et al. An estimate of amyotrophic lateral sclerosis heritability using twin data. J Neurol Neurosurg Psychiatry 81 (2010), 1324–1326.
81. 81 Wroe, R, Wai-Ling Butler, A, Andersen, PM, Powell, JF, Al-Chalabi, A, ALSOD: the Amyotrophic Lateral Sclerosis Online Database. Amyotroph Lateral Scler 9 (2008), 249–250.
82. 82 Kenna, KP, McLaughlin, RL, Hardiman, O, Bradley, DG, Using reference databases of genetic variation to evaluate the potential pathogenicity of candidate disease variants. Hum Mutat 34 (2013), 836–841.
83. 83 Hanby, MF, Scott, KM, Scotton, W, et al. The risk to relatives of patients with sporadic amyotrophic lateral sclerosis. Brain 134 (2011), 3454–3457.
84. 84 DeJesus-Hernandez, M, Mackenzie, IR, Boeve, BF, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 72 (2011), 245–256.
85. 85 Renton, AE, Majounie, E, Waite, A, et al., the ITALSGEN Consortium. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 72 (2011), 257–268.
86. 86 Shatunov, A, Mok, K, Newhouse, S, et al. Chromosome 9p21 in sporadic amyotrophic lateral sclerosis in the UK and seven other countries: a genome-wide association study. Lancet Neurol 9 (2010), 986–994.
87. 87 van Es, MA, Veldink, JH, Saris, CG, et al. Genome-wide association study identifies 19p13.3 (UNC13A) and 9p21.2 as susceptibility loci for sporadic amyotrophic lateral sclerosis. Nat Genet 41 (2009), 1083–1087.
88. 88 Andersen, PM, Al-Chalabi, A, Clinical genetics of amyotrophic lateral sclerosis: what do we really know?. Nat Rev Neurol 7 (2011), 603–615.
89. 89 Fahey, C, Byrne, S, McLaughlin, R, et al. Analysis of the hexanucleotide repeat expansion and founder haplotype at C9ORF72 in an Irish psychosis case-control sample. Neurobiol Aging 35 (2014), 1510.e1–1510.e5.
90. 90 Kertesz, A, Ang, LC, Jesso, S, et al. Psychosis and hallucinations in frontotemporal dementia with the C9ORF72 mutation: a detailed clinical cohort. Cogn Behav Neurol 26 (2013), 146–154.
91. 91 Hardy, J, Rogaeva, E, Motor neuron disease and frontotemporal dementia: sometimes related, sometimes not. Exp Neurol 262 (2014), 75–83.
92. 92 Barbeito, AG, Martinez-Palma, L, Vargas, MR, et al. Lead exposure stimulates VEGF expression in the spinal cord and extends survival in a mouse model of ALS. Neurobiol Dis 37 (2010), 574–580.
93. 93 Kamel, F, Umbach, DM, Stallone, L, Richards, M, Hu, H, Sandler, DP, Association of lead exposure with survival in amyotrophic lateral sclerosis. Environ Health Perspect 116 (2008), 943–947.
94. 94 Keren, N, Scott, KM, Tsuda, M, et al. Evidence of an environmental effect on survival in ALS. Amyotroph Lateral Scler Frontotemporal Degener 15 (2014), 528–533.
95. 95 Eum, KD, Seals, RM, Taylor, KM, et al. Modification of the association between lead exposure and amyotrophic lateral sclerosis by iron and oxidative stress related gene polymorphisms. Amyotroph Lateral Scler Frontotemporal Degener 16 (2015), 72–79.
96. 96 Fogh, I, Lin, K, Tiloca, C, et al. Association of a locus in the CAMTA1 gene with survival in patients with sporadic amyotrophic lateral sclerosis. JAMA Neurol 73 (2016), 812–820.
97. 97 Alanazy, MH, White, C, Korngut, L, Diagnostic yield and cost-effectiveness of investigations in patients presenting with isolated lower motor neuron signs. Amyotroph Lateral Scler Frontotemporal Degener 15 (2014), 414–419.
98. 98 EFNS Task Force on Diagnosis and Management of Amyotrophic Lateral Sclerosis, Andersen, PM, Abrahams, S, et al. EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS)–revised report of an EFNS task force. Eur J Neurol 19 (2012), 360–375.
99. 99 Brooks, BR, Versailles minimal dataset for diagnosis of ALS: a distillate of the 2nd Consensus Conference on accelerating the diagnosis of ALS. Versailles 2nd Consensus Conference participants. Amyotroph Lateral Scler Other Motor Neuron Disord 1:suppl 1 (2000), S79–S81.
100. 100 Sanderson, AB, Arnold, WD, Elsheikh, B, Kissel, JT, The clinical spectrum of isolated peripheral motor dysfunction. Muscle Nerve 51 (2015), 358–362.
101. 101 Donaldson, R, Li, J, Li, Y, Clinical significance of cation channel antibodies in motor neuron disease. Muscle Nerve 54 (2016), 228–231.
102. 102 Kollewe, K, Wurster, U, Sinzenich, T, et al. Anti-ganglioside antibodies in amyotrophic lateral sclerosis revisited. PLoS ONE, 10, 2015, e0125339.
103. 103 Gaiottino, J, Norgren, N, Dobson, R, et al. Increased neurofilament light chain blood levels in neurodegenerative neurological diseases. PLoS ONE, 8, 2013, e75091.
104. 104 Steinacker, P, Feneberg, E, Weishaupt, J, et al. Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients. J Neurol Neurosurg Psychiatry 87 (2016), 12–20.
105. 105 Puentes, F, Topping, J, Kuhle, J, et al. Immune reactivity to neurofilament proteins in the clinical staging of amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 85 (2014), 274–278.
106. 106 Roche, JC, Rojas-Garcia, R, Scott, KM, et al. A proposed staging system for amyotrophic lateral sclerosis. Brain 135 (2012), 847–852.
107. 107 Agosta, F, Al-Chalabi, A, Filippi, M, et al., the WFN Research Group on ALS/MND. The El Escorial criteria: strengths and weaknesses. Amyotroph Lateral Scler Frontotemporal Degener 16 (2015), 1–7.
108. 108 Spinelli, EG, Agosta, F, Ferraro, PM, et al. Brain MR imaging in patients with lower motor neuron-predominant disease. Radiology 280 (2016), 545–556.
109. 109 Brettschneider, J, Del Tredici, K, Toledo, JB, et al. Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. Ann Neurol 74 (2013), 20–38.
110. 110 Kassubek, J, Müller, HP, Del Tredici, K, et al. Diffusion tensor imaging analysis of sequential spreading of disease in amyotrophic lateral sclerosis confirms patterns of TDP-43 pathology. Brain 137 (2014), 1733–1740.
111. 111 Treede, RD, Rief, W, Barke, A, et al. A classification of chronic pain for ICD-11. Pain 156 (2015), 1003–1007.
112. 112 Rajakulendran, S, Dua, T, Harper, M, Shakir, R, The classification of neurological disorders in the 11th revision of the International Classification of Diseases (ICD-11). J Neurol Neurosurg Psychiatry 85 (2014), 952–953.
113. 113 Rief, W, Kaasa, S, Jensen, R, et al. The need to revise pain diagnoses in ICD-11. Pain 149 (2010), 169–170.
114. 114 Jette, N, Beghi, E, Hesdorffer, D, et al. ICD coding for epilepsy: past, present, and future—a report by the International League Against Epilepsy Task Force on ICD codes in epilepsy. Epilepsia 56 (2015), 348–355.
115. 115 Stone, J, Hallett, M, Carson, A, Bergen, D, Shakir, R, Functional disorders in the Neurology section of ICD-11: a landmark opportunity. Neurology 83 (2014), 2299–2301.
116. 116 Statland, JM, Barohn, RJ, McVey, AL, Katz, JS, Dimachkie, MM, Patterns of weakness, classification of motor neuron disease, and clinical diagnosis of sporadic amyotrophic lateral sclerosis. Neurol Clin 33 (2015), 735–748.
117. 117 Statland, JM, Barohn, RJ, Dimachkie, MM, Floeter, MK, Mitsumoto, H, Primary lateral sclerosis. Neurol Clin 33 (2015), 749–760.
118. 118 Liewluck, T, Saperstein, DS, Progressive muscular atrophy. Neurol Clin 33 (2015), 761–773.
119. 119 Jawdat, O, Statland, JM, Barohn, RJ, Katz, JS, Dimachkie, MM, Amyotrophic lateral sclerosis regional variants (brachial amyotrophic diplegia, leg amyotrophic diplegia, and isolated bulbar amyotrophic lateral sclerosis). Neurol Clin 33 (2015), 775–785.
120. 120 First, MB, Reed, GM, Hyman, SE, Saxena, S, The development of the ICD-11 Clinical Descriptions and Diagnostic Guidelines for Mental and Behavioural Disorders. World Psychiatry 14 (2015), 82–90.
121. 121 Wagner, L, Rechtman, L, Jordan, H, et al. State and metropolitan area-based amyotrophic lateral sclerosis (ALS) surveillance. Amyotroph Lateral Scler Frontotemporal Degener, 2015, 1–7.
122. 122 Stein, DJ, Kogan, CS, Atmaca, M, et al. The classification of Obsessive-Compulsive and Related Disorders in the ICD-11. J Affect Disord 190 (2016), 663–674.
123. 123 Al-Chalabi, A, Calvo, A, Chio, A, et al. Analysis of amyotrophic lateral sclerosis as a multistep process: a population-based modelling study. Lancet Neurol 13 (2014), 1108–1113.
124. 124 Balendra, R, Jones, A, Jivraj, N, et al. the UK-MND LiCALS Study Group, Mito Target ALS Study Group. Use of clinical staging in amyotrophic lateral sclerosis for phase 3 clinical trials. J Neurol Neurosurg Psychiatry 86 (2015), 45–49.
125. 125 Chiò, A, Hammond, ER, Mora, G, Bonito, V, Filippini, G, Development and evaluation of a clinical staging system for amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 86 (2015), 38–44.